English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 April 2020, 15:30 HKT/SGT

Source: TNB AURA
TNB Aura launches Special Situations Fund, backing tech startups with US$2M each

SINGAPORE, Apr 2, 2020 - (ACN Newswire) - WHO declared COVID-19 a pandemic, its message balancing the inevitability of the virus' global ramifications, with the observation that governments, businesses, and individuals still possess the critical ability to alter the outbreak's trajectory. With businesses abruptly curtailing operations across most sectors, only a select set of companies are well positioned to take advantage of the current situation, while the majority are not.

TNB Aura Co-founders and Managing Partners Vicknesh R Pillay and Charles Wong.

TNB Aura has launched a new Special Situations Fund, backing tech companies impacted by the pandemic with ~US$2M each.

"While we continue investing in growth companies in South East Asia via our first fund, and soon to be second, we see an opportunity to support great companies which are facing near-term cash flows issues as a result of The COVID-19 black swan event," Co-founder and Managing Partner, Vicknesh R Pillay commented. "Our highly selective and hands on approach to investing has proven resilient, reflecting as such in a majority of our portfolio companies. With our financial acumen, we assist our investee companies to be nimble in the manner in which they manage their cash flow, budgeting and talent optimization through volatility."

By providing an extended runway of 12-18 months to weather the headwinds, the fund serves to aid companies in returning their focus to achieving their targeted milestones. "We are investing for the long term, and seek to provide an encouraging narrative to the ecosystem at this critical time. Ultimately, we believe in strong fundamentals, and in the ability of selected companies to both weather the current storm and come out stronger on the other side," said Co-founder and Managing Partner, Charles Wong.

"With the market having previously witnessed a glut of over-valued deals, and today, a current value dislocation, TNB AURA is targeting value deals of high quality for this new fund," Pillay added. TNB AURA aims to turnaround funding within 1-2 months, with the fund open to a range of funding structures such as convertible notes or direct equity. For all interested applicants, please apply through the Special Situations Fund Form. All applications will be dealt with, with the highest confidentiality.

About TNB Aura
TNB Aura is a Singapore headquartered venture capital firm focused on Series A and B technology investments in the region. Founded by entrepreneurs and fund managers who have established, grown and exited several businesses, TNB Aura looks to become the marquee venture capital fund in South East Asia. We believe in people and companies with strong fundamentals, and invest $1mil-$5mil into the next wave of technology-led high growth companies.

For further information, please contact:
Vicknesh R Pillay
Managing Partner, TNB Aura
E: [email protected]
M: +65 9009 6164

Charles Wong
Managing Partner, TNB Aura
E: [email protected]
M: +65 8250 2525

Topic: Press release summary
Sectors: FinTech/Chains, Venture Capital
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
New Study Underscores How Heated Tobacco Products Are Disrupting the Cigarette Industry  
May 31, 2020 11:00 HKT/SGT
I-intern's co-founder Delysia Song: Guiding Chinese Students to a Future in America  
May 30, 2020 16:00 HKT/SGT
After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test  
May 30, 2020 10:00 HKT/SGT
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody  
May 29, 2020 14:54 HKT/SGT
Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division  
May 29, 2020 14:47 HKT/SGT
DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers  
May 29, 2020 11:05 HKT/SGT
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials   
May 29, 2020 10:31 HKT/SGT
Paice, Abell, and Daimler Agree to License Patented Technology  
May 29, 2020 06:00 HKT/SGT
Sino Biopharmaceutical Announces 2020 First Quarterly Results  
May 28, 2020 19:59 HKT/SGT
Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer  
May 28, 2020 18:18 HKT/SGT
More Press release >>
More events >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575